Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum: Evidence for a lobular- and laminar-specific dopamine innervation

Neuropsychopharmacology

Volumn 22, Issue 5, 2000, Pages 466-472

  Melchitzky, Darlene S ^a   Lewis, David A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cerebellar vermis; Dopamine beta hydroxylase; Monkey; Purkinje cells; Schizophrenia

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; CEREBELLUM; COGNITION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MONKEY; MOTOR PERFORMANCE; NERVE FIBER; NERVE PROJECTION; NONHUMAN; PRIORITY JOURNAL; PURKINJE CELL; SCHIZOPHRENIA;

ANIMALS; AXONS; CARRIER PROTEINS; CEREBELLUM; DOPAMINE; DOPAMINE BETA-HYDROXYLASE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; TYROSINE 3-MONOOXYGENASE;

EID: 0034057477     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00139-6     Document Type: Article

References (56)

1. Akil M., Lewis D.A. The dopaminergic innervation of monkey entorhinal cortex. Cereb Cortex. 3:1993;533-550.
2. Andreasen N.C., O'Leary D.S., Cizaldo T., Arndt S., Rezai K., Boles Ponto L.L., Watkins G.L., Hichwa R.D. Schizophrenia and cognitive dysmetria. A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry Proc Natl Acad Sci USA. 93:1996;9985-9990.
3. Berger B., Gaspar P., Verney C. Dopaminergic innervation of the cerebral cortex. Unexpected differences between rodents and primates TINS. 14:1991;21-27.
4. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys. Science. 205:1979;929-932.
5. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia. New perspectives and therapeutic implications Life Sci. 61:1997;75-94.
6. Chrapusta S.J., Egan M.F., Masserano J.M., Wyatt R.J. Dopamine release in the rat cerebellum and hippocampus. A tissue 3-methoxytyramine study Brain Res. 655:1994;271-275.
7. Ciliax B.J., Drash G.W., Staley J.K., Haber S., Mobley C.J., Miller G.W., Mufson E.J., Mash D.C., Levey A.I. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol. 409:1999;38-56.
8. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., Niznik H.B., Levey A.I. The dopamine transporter. Immunochemical characterization and localization in brain J Neurosci. 15:1995;1714-1723.
9. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia. A review and reconceptualization Am J Psychiat. 148:1991;1474-1486.
10. 3 receptor in the rat brain. Neuroscience. 65:1995;731-745.
11. Freed C., Revay R., Vaughan R.A., Kriek E., Grant S., Uhl G.R., Kuhar M.J. Dopamine transporter immunoreactivity in rat brain. J Comp Neurol. 359:1995;340-349.
12. Fuchs A.F., Robinson F.R., Straube A. Role of the caudal fastigial nucleus in saccade generation. J Neurophysiol. 70:1993;1723-1740.
13. Goldman-Rakic P.S. The cortical dopamine system. Role in memory and cognition Goldstein D.S., Eisenhofer G., McCarty R. Catecholamines. Bridging Basic Science with Clinical Medicine:1998;707-711 Academic Press, San Diego.
14. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity. A hypothesis for the etiology of schizophrenia Neuroscience. 41:1991;1-24.
15. Holzman P.S., Proctor L.R., Hughes D.W. Eye tracking patterns in schizophrenia. Science. 181:1973;179-181.
16. Hökfelt T., Fuxe K. Cerebellar monoamine nerve terminals, a new type of afferent fiber to the cortex cerebelli. Exp Brain Res. 9:1969;63-72.
17. Hsu S.-M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. A comparison between ABC and unlabeled antibody (PAP) procedures J Histochem Cytochem. 29:1981;577-580.
18. Hume S.P., Lammerstma A.A., Myers R., Rajeswaran S., Bloomfield P.M., Ashworth S., Fricker R.A., Torres E.M., Watson I., Jones T. The potential high-resolution positron emission tomography to monitor striatal dopamine function in rat models of disease. J Neurosci Meth. 67:1996;103-112.
19. Hutton S., Kennard C. Oculomotor abnormalities in schizophrenia. A critical review Neurology. 50:1998;604-609.
20. Ikai Y., Takada M., Shinonaga Y., Mizuno N. Dopaminergic and nondopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei. Neuroscience. 51:1992;719-728.
21. Ito M. The Cerebellum and Neural Control. 1984;Raven Press, New York.
22. Jaber M., Jones S., Giros B., Caron M.G. The dopamine transporter. A crucial component regulating dopamine transmission Movem Disord. 12:1997;629-633.
23. Jacobsen L.K., Giedd J.N., Berquin P.C., Krain A.L., Hamburger S.D., Kumra S., Rapoport J.L. Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. Am J Psychiat. 154:1997;1663-1669.
24. Kapur S., Zipursky R.B., Remington G., Jones C., McKay G., Houle S. PET evidence that Loxapine is an equipotent blocker of 5-HT2 and D2 receptors. Implications for the theapeutics of schizophrenia Am J Psychiat. 154:1997;1525-1529.
25. Khan Z.U., Gutiérrez A., Martín R., Peñafiel A., Rivera A., de la Calle A. Differential regional and cellular distribution of dopamine D2-like receptors. An immunocytochemical study of subtype-specific antibodies in rat and human brain J Comp Neurol. 402:1998;353-371.
26. Kim S.-G., Ugurbil K., Strick P.L. Activation of a cerebellar output nucleus during cognitive processing. Science. 265:1994;949-951.
27. Kuhar M.J. Recent biochemical studies of the dopamine transporter - A CNS drug target. Life Sci. 62:1998;1573-1575.
28. Levy D.L., Holzman P.S., Matthysse S., Mendell N.R. Eye tracking and schizophrenia. A selective review Schizophr Bull. 20:1994;47-62.
29. Lewis D.A., Melchitzky D.S., Haycock J.W. Four isoforms of tyrosine hydroxylase are expressed in human brain. Neuroscience. 54:1993;477-492.
30. Lewis D.A., Melchitzky D.S., Haycock J.W. Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain. Brain Res. 656:1994;1-13.
31. Lewis D.A., Sesack S.R. Dopamine systems in the primate brain. Bloom F.E., Björklund A., Hökfelt T. Handbook of Chemical Neuroanatomy. 1997;261-373 Elsevier Science, Amsterdam.
32. Lewis D.A., Sesack S.R., Levey A.I., Rosenberg D.R. Dopamine axons in primate prefrontal cortex. Specificity of distribution, synaptic targets, and development Goldstein D., Eisenhofer G., McCarty R. Advances in Pharmacology. Catecholamines: Bridging Basic Science with Clinical Medicine:1998;703-706 Academic Press, San Diego.
33. Lindvall O., Björklund A. Organization of catecholamine neurons in the rat central nervous system. Iversen L.L., Iversen S.D., Snyder S.H. Handbook of Psychopharmacology, Vol. 9. 1978;139-231 Plenum, New York.
34. Madigan J.C. Jr., Carpenter M.B. Cerebellum of the Rhesus Monkey. Atlas of Lobules, Laminae, and Folia in Sections:1971;University Park Press, Baltimore.
35. Middleton F.A., Strick P.L. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science. 266:1994;458-461.
36. Miller G.W., Staley J.K., Heilman C.J., Perez J.T., Mash D.C., Rye D.B., Levey A.I. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol. 41:1997;530-539.
37. Noack H.J., Lewis D.A. Antibodies directed against tyrosine hydroxylase differentially recognize noradrenergic axons in monkey neocortex. Brain Res. 500:1989;313-324.
38. Nyberg S., Farde L., Halldin C. Test-retest reliability of central [11c]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiat Res. 67:1996;163-171.
39. Panagopoulos N.T., Papadopoulos G.C., Mastokis N.A. Dopaminergic innervation and binding in the rat cerebellum. Neurosci Lett. 130:1991;208-212.
40. Petersen S.E., Fiez J.A. The processing of single words studied with positron emission tomography. Annu Rev Neurosci. 16:1993;509-530.
41. Pucak M.L., Levitt J.B., Lund J.S., Lewis D.A. Patterns of intrinsic and associational circuitry in monkey prefrontal cortex. J Comp Neurol. 376:1996;614-630.
42. Ryding E., Decety J., Sjöholm H., Stenberg G., Ingvar D.H. Motor imagery activates the cerebellum regionally. A SPECT rCBF study with. 99mTc-HMPAO.(Cog Brain Res 1):1993;94-99.
43. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex. Involvement in working memory Science. 251:1991;947-950.
44. Sawaguchi T., Matsumura M., Kubota K. Dopamine enhances the neuronal activity of spatial short-term memory task in the primate prefrontal cortex. Neurosci Res. 5:1988;465-473.
45. Schmahmann J.D. An emerging concept. The cerebellar contribution to higher function. Arch Neurol. 48:1991;1178-1187.
46. Schmahmann J.D., Sherman J.C. The cerebellar cognitive affective syndrome. Brain. 121:1998;561-579.
47. Sesack S.R., Hawrylak V.A., Matus C.V., Guido M.A., Levey A.I. Dopamine axon vericosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 18:1998;2697-2708.
48. Snyder S.H. Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiat. 27:1972;169-179.
49. Steinberg J.L., Devous M.D., Moeller F.G., Paulman R.G., Raese J.D., Gregory R.R. Cerebellar blood flow in schizophrenic patients and normal control subjects. Psychiatry Res : Neuroimaging. 61:1995;15-31.
50. Tran K.D., Smutzer G.S., Doty R.L., Arnold S.E. Reduced Purkinje cell size in the cerebellar vermis of elderly patients with schizophrenia. Am J Psychiat. 155:1998;1288-1290.
51. Vallabhajosula S., Hirschowitz J., Machac J. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients. J Nuclear Med. 38:1997;203-207.
52. Vilis T., Hore J. Characteristics of saccadic dysmetria in monkeys during reversible lesions of medial cerebellar nuclei. J Neurophysiol. 46:1981;828-838.
53. Volkow N.D., Levy A., Brodie J.D., Wolf A.P., Cancro R., Van Gelder P., Henn F. Low cerebellar metabolism in medicated patients with chronic schizophrenia. Am J Psychiat. 149:1992;686-688.
54. Wang G.J., Volkow N.D., Levy A., Fowler J.S., Logan J., Alexoff D., Hitzemann R.J., Schyler D.J. MR-PET image coregistration for quantitation of striatal dopamine D2 receptors. J Comput Assist Tomog. 20:1996;423-428.
55. Weinberger D.R., Kleinman J.E., Luchins D.J., Bigelow L.B., Wyatt R.J. Cerebellar pathology in schizophrenia. A controlled postmortem study Am J Psychiat. 137:1980;359-361.
56. Wolf M.E., LeWitt P.A., Bannon M.J., Dragovic L.J., Kapatos G. Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate. J Neurochem. 56:1991;1191-1200.